V
Vanessa Monteil
Researcher at Karolinska Institutet
Publications - 32
Citations - 2861
Vanessa Monteil is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 10, co-authored 25 publications receiving 1721 citations. Previous affiliations of Vanessa Monteil include Karolinska University Hospital & Public Health Agency of Sweden.
Papers
More filters
Journal ArticleDOI
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.
Vanessa Monteil,Hyesoo Kwon,Patrícia Rezende do Prado,Astrid Hagelkruys,Reiner A. Wimmer,Martin Stahl,Alexandra Leopoldi,Elena Garreta,Carmen Hurtado del Pozo,Felipe Prosper,Juan P. Romero,Gerald Wirnsberger,Haibo Zhang,Arthur S. Slutsky,Ryan K. Conder,Nuria Montserrat,Ali Mirazimi,Ali Mirazimi,Josef M. Penninger,Josef M. Penninger +19 more
TL;DR: It is demonstrated that hrsACE2 can significantly block early stages of SARS-CoV-2 infections, and is proposed that inhibiting this interaction might be used in treating patients with COVID-19.
Journal ArticleDOI
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
Justin Stebbing,Venkatesh Krishnan,Stephanie de Bono,Silvia Ottaviani,Giacomo Casalini,Peter J. Richardson,Vanessa Monteil,Volker M. Lauschke,Ali Mirazimi,Sonia Youhanna,Yee-Joo Tan,Yee-Joo Tan,Fausto Baldanti,Antonella Sarasini,Jorge A. Ross Terres,Brian J. Nickoloff,Richard E. Higgs,Guilherme Rocha,Nicole L. Byers,Douglas E Schlichting,Ajay Nirula,Anabela Cardoso,Mario Corbellino +22 more
TL;DR: In a case series of patients with bilateral COVID‐19 pneumonia, baricitinib treatment was associated with clinical and radiologic recovery, a rapid decline in SARS‐CoV‐2 viral load, inflammatory markers, and IL‐6 levels, and these data support further evaluation of the anti‐cytokine and anti‐viral activity of baricit inib and support its assessment in randomized trials in hospitalized CO VID‐19 patients.
Journal ArticleDOI
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.
Justin Stebbing,Ginés Sánchez Nievas,Marco Falcone,Sonia Youhanna,Peter D. Richardson,Silvia Ottaviani,Joanne X. Shen,Christian Sommerauer,Giusy Tiseo,Lorenzo Ghiadoni,Agostino Virdis,Fabio Monzani,Luis Romero Rizos,Francesco Forfori,Almudena Avendaño Céspedes,Salvatore De Marco,Laura Carrozzi,Fabio Lena,Pedro Manuel Sánchez-Jurado,Leonardo Gianluca Lacerenza,Nencioni Cesira,David Caldevilla Bernardo,Antonio Perrella,Laura Niccoli,Lourdes Sáez Méndez,Daniela Matarrese,Delia Goletti,Yee-Joo Tan,Vanessa Monteil,George Dranitsaris,Fabrizio Cantini,Alessio Farcomeni,Shuchismita Dutta,Stephen K. Burley,Haibo Zhang,Mauro Pistello,William W. Li,Marta Mas Romero,Fernando Andrés Pretel,Rafaela Sánchez Simón-Talero,Rafael García-Molina,Claudia Kutter,James H. Felce,Zehra F. Nizami,Andras G. Miklosi,Josef M. Penninger,Josef M. Penninger,Francesco Menichetti,Ali Mirazimi,Pedro Abizanda,Volker M. Lauschke +50 more
TL;DR: It is found that baricitinib exerts activity rapidly through the inhibition of host proteins (numb-associated kinases), uniquely among antivirals, and is associated with beneficial outcomes including in severely ill elderly patients, data that incentivize further randomized controlled trials.
Journal ArticleDOI
Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context
Pascal Mertens,Nathalie De Vos,Delphine Martiny,Christian Jassoy,Ali Mirazimi,Lize Cuypers,Sigi Van den Wijngaert,Vanessa Monteil,Pierrette Melin,Karolien Stoffels,Nicolas Yin,Davide Mileto,Sabrina Delaunoy,Henri Magein,Katrien Lagrou,Justine Bouzet,Gabriela Serrano,Magali Wautier,Thierry Leclipteux,Marc Van Ranst,Olivier Vandenberg,Olivier Vandenberg +21 more
TL;DR: The CO VID-19 Ag Respi-Strip represents a promising rapid SARS-CoV-2 antigen assay for the first-line diagnosis of COVID-19 in 15 min at the peak of the pandemic.
Posted ContentDOI
Development and potential usefulness of the COVID-19 Ag Respi-Strip® diagnostic assay in a pandemic context
Pascal Mertens,Nathalie De Vos,Delphine Martiny,Christian Jassoy,Ali Mirazimi,Lize Cuypers,Sigi Van den Wijngaert,Vanessa Monteil,Pierrette Melin,Karolien Stoffels,Nicolas Yin,Davide Mileto,Sabrina Delaunoy,Henri Magein,Katrien Lagrou,Justine Bouzet,Gabriela Serrano,Magali Wautier,Thierry Leclipteux,Marc Van Ranst,Olivier Vandenberg,Olivier Vandenberg,Béatrice Gulbis,Françoise Brancart,François Bry,Brigitte Cantinieaux,Francis Corazza,Frédéric Cotton,Maud Dresselhuis,Bhavna Mahadeb,Olivier Roels,Jacques Vanderlinden +31 more
TL;DR: In this paper, an immunochromatographic (ICT) assay for the rapid detection of SARS-CoV-2 antigen on nasopharyngeal specimen has been developed to identify positive COVID-19 patients allowing prompt clinical and quarantine decisions.